Meningococcal vaccines and herd immunity: lessons learned from serogroup C conjugate vaccination programs

Cited by (199)

Items 101–199 of 199

1. Diversity of factor H-binding protein in Neisseria meningitidis carriage isolates
   Jane W. Marsh, Kathleen A. Shutt, Rolando Pajón, Mary M. Tulenko, Stephen Liu, Rosemary A. Hollick, Julia A. Kiehlbauch, Thomas A. Clark, David S. Stephens, Kathryn E. Arnold et al. · 2011 · Vaccine
2. Meningococcal Carriage in Military Recruits and University Students during the Pre MenB Vaccination Era in Greece (2014-2015)
   Kyriaki Tryfinopoulou, Κωνσταντίνος Κεσανόπουλος, Athanasia Xirogianni, Νεκτάριος Μαρμαράς, Anastasia Papandreou, Vassiliki Papaevangelou, Maria N Tsolia, Aftab Jasir, Georgina Tzanakaki · 2016 · PLoS ONE
3. ‘Be on the TEAM’ Study (Teenagers Against Meningitis): protocol for a controlled clinical trial evaluating the impact of 4CMenB or MenB-fHbp vaccination on the pharyngeal carriage of meningococci in adolescents
   Jeremy Carr, Emma L. Plested, Parvinder K. Aley, Susana Camara, Kimberly Davis, Jenny M. MacLennan, Steve J Gray, Saul N. Faust, Ray Borrow, Hannah Christensen et al. · 2020 · BMJ Open
4. Salivary and Serum Antibody Response Against Neisseria meningitidis After Vaccination With Conjugate Polysaccharide Vaccines in Ethiopian Volunteers
   Guro K. Bårnes, Bereket Workalemahu, Paul A. Kristiansen, Demissew Beyene, Behailu Merdekios, Paulos Fissiha, Abraham Aseffa, Dominique A. Caugant, Lisbeth Meyer Næss · 2016 · Scandinavian Journal of Immunology
5. Carriage prevalence of Neisseria meningitidis in China, 2005–2022: a systematic review and meta-analysis
   Mengmeng Yue, Juan Xu, Jianxing Yu, Zhujun Shao · 2022 · BMC Infectious Diseases
6. A Consensus Statement
   Ricardo Walter Rüttimann, Angela S. de Gentile, Mercedes Macías Parra, Xavier Sáez‐Llorens, Marco Aurélio Palazzi Sáfadi, Marı́a Elena Santolaya · 2014 · The Pediatric Infectious Disease Journal
7. Effect of Increased CRM197Carrier Protein Dose on Meningococcal C Bactericidal Antibody Response
   Lucia H. Lee, Milan S. Blake · 2012 · Clinical and Vaccine Immunology
8. Anti-infective vaccination in the 21st century—new horizons for personal and public health
   Ingrid Lea Scully, Kena A. Swanson, Luke Green, Kathrin Ute Jansen, Annaliesa S. Anderson · 2015 · Current Opinion in Microbiology
9. The next chapter for group B meningococcal vaccines
   Nelson Wang, Andrew John Pollard · 2017 · Critical Reviews in Microbiology
10. Controlling serogroup B invasive meningococcal disease: the Canadian perspective
    Julie A. Bettinger, Shelley L. Deeks, Scott A. Halperin, Raymond S. W. Tsang, David W. Scheifele · 2013 · Expert Review of Vaccines
11. Kinetics of Immune Responses to Nasal Challenge With Meningococcal Polysaccharide One Year After Serogroup-C Glycoconjugate Vaccination
    James B. Wing, L. E. Smart, Ray Borrow, Jamie Findlow, Helen Findlow, Andrew William Heath, Robert Charles Read · 2011 · Clinical Infectious Diseases
12. Typing complex meningococcal vaccines to understand diversity and population structure of key vaccine antigens
    Charlene M.C. Rodrigues, Hannah Chan, Caroline Vipond, Keith A. Jolley, Odile Barbara Harrison, Jun X. Wheeler, Gail C. Whiting, Ian M. Feavers, Martin C. J. Maiden · 2018 · Wellcome Open Research
13. A Randomized Trial to Assess Safety and Immunogenicity of Alternative Formulations of a Quadrivalent Meningococcal (A, C, Y, and W-135) Tetanus Protein Conjugate Vaccine in Toddlers
    Jodie McVernon, Terry M. Nolan, Peter Richmond, Graham Reynolds, Michael D. Nissen, Stephen Bernard Lambert, Helen Siobhan Marshall, Thomas Papa, Christine Rehm · 2011 · The Pediatric Infectious Disease Journal
14. Cobertura da vacina meningocócica C nos estados e regiões do Brasil em 2012
    Rosália Garcia Neves, Andrea Tuchtenhagen Wendt, Caroline dos Santos Costa, Thaynã Ramos Flores, Ana Gonçalves Soares, Fernando C. Wehrmeister · 2016 · Revista Brasileira de Medicina de Família e Comunidade
15. Missed opportunities in child healthcare
    Linda Jonker, Ethelwynn L. Stellenberg · 2014 · African Journal of Primary Health Care & Family Medicine
16. Methodological Concerns with Economic Evaluations of Meningococcal Vaccines
    Teresa L. Kauf · 2010 · PharmacoEconomics
17. 4CMenB vaccine and its role in preventing transmission and inducing herd immunity
    Mark McMillan, Helen Siobhan Marshall, Peter Richmond · 2021 · Expert Review of Vaccines
18. Meningococcal carriage in children and young adults in the Philippines: a single group, cross-sectional study
    Maria L. A. Gonzales, Véronique Bianco, Andrew Vyse · 2016 · Epidemiology and Infection
19. Meningococcal ACWY vaccine uptake and awareness among student freshers enrolled at Northern Ireland universities
    Peter J. A. Moore, Beverley Cherie Millar, John Edmund Moore · 2017 · International Journal of Adolescent Medicine and Health
20. Cost-effectiveness of meningococcal vaccination of Norwegian teenagers with a quadrivalent ACWY conjugate vaccine
    Sara Viksmoen Watle, Lisbeth Meyer Næss, Gro Tunheim, Dominique A. Caugant, Torbjørn Fosen Wisløff · 2021 · Human Vaccines & Immunotherapeutics
21. Serogroup A meningococcal conjugate vaccines in Africa
    Paul A. Kristiansen, Hannah Joan Jørgensen, Dominique A. Caugant · 2015 · Expert Review of Vaccines
22. Bioanalysis of Meningococcal Vaccines
    Neil Ravenscroft, Jun X. Wheeler, Christopher Jones · 2010 · Bioanalysis
23. Modelled evaluation of multi-component meningococcal vaccine (Bexsero®) for the prevention of invasive meningococcal disease in infants and adolescents in the UK
    Jasper Huels, Karen M. Clements, Lisa J. McGarry, G. J. HILL, James Wassil, Sophia Kessabi · 2013 · Epidemiology and Infection
24. Impact on disease incidence of a routine universal and catch-up vaccination strategy against Neisseria meningitidis C in Tuscany, Italy
    Angela Bechini, Miriam Levi, Sara Boccalini, Emilia Tiscione, Emanuela Balocchini, Clementina Canessa, Chiara Azzari, Paolo Bonanni · 2012 · Vaccine
25. MenACWY-TT is immunogenic when co-administered with Tdap and AS04-HPV16/18 in girls and young women: Results from a phase III randomized trial
    Luis Rivera, Pornthep Chanthavanich, Airi Põder, Pemmaraju Venkata Suryakiran, Archana M. Jastorff, Marie Van der Wielen · 2018 · Vaccine
26. Evaluation of meningococcal serogroup C conjugate vaccine programs in Canadian children: Interim analysis
    Julie A. Bettinger, David W. Scheifele, Scott A. Halperin, James D. Kellner, Otto G. Vanderkooi, Anthony Bernard Schryvers, Gaston De Serres, Joenel Alcantara · 2012 · Vaccine
27. Low Uptake of Meningococcal C Vaccination in France
    Marion Le Maréchal, Nelly Agrinier, Lisa Fressard, Pierre Verger, Céline Pulcini · 2017 · The Pediatric Infectious Disease Journal
28. Narrative review of methods and findings of recent studies on the carriage of meningococci and other Neisseria species in the African Meningitis Belt
    Brian M Greenwood, Abraham Aseffa, Dominique A. Caugant, Kanny Diallo, Paul A. Kristiansen, Martin C. J. Maiden, James M. Stuart, Caroline L. Trotter · 2018 · Tropical Medicine & International Health
29. Epidemiology of two decades of invasive meningococcal disease in the Republic of Ireland: an analysis of national surveillance data on laboratory-confirmed cases from 1996 to 2016
    Désirée E. Bennett, Piaras P. O’Lorcain, Sophia Morgan, Suzanne M. Cotter, M Cafferkey, Robert Cunney · 2019 · Epidemiology and Infection
30. Phenotypic characterization of Neisseria meningitidis strains isolated from invasive meningococcal disease in Brazil from 2002 to 2017
    Maria Cecília Gorla, Angela Pires Brandão, Juliana Maíra Watanabe Pinhata, Camile de Moraes, Gabriela M. Pereira, Ana Paula Silva de Lemos · 2019 · Access Microbiology
31. Meningococcal B vaccination strategies and their practical application in Italy
    Roberto Gasparini, Daniela Amicizia, Piero Luigi Lai, Donatella Panatto · 2015 · Journal of preventive medicine and hygiene
32. Establishment of the European meningococcal strain collection genome library (EMSC-GL) for the 2011 to 2012 epidemiological year
    Holly B. Bratcher, Carina Brehony, Sigrid Heuberger, Despo Pieridou-Bagatzouni, Pavla Křížová, Steen Hoffmann, Maija Toropainen, Muhamed‐Kheir Taha, Heike Claus, Georgina Tzanakaki et al. · 2018 · Eurosurveillance
33. Immunogenicity and Safety of Combined Tetanus, Reduced Diphtheria, Acellular Pertussis Vaccine when Co-Administered with Quadrivalent Meningococcal Conjugate and Human Papillomavirus Vaccines in Healthy Adolescents
    William Johnston · 2014 · Journal of Vaccines & Vaccination
34. Meningococcal Capsular Group B Vaccines
    Dan M. Granoff, Andrew John Pollard, Lee H. Harrison · 2017 · Elsevier eBooks
35. A Randomized Study to Evaluate the Immunogenicity and Safety of a Heptavalent Diphtheria, Tetanus, Pertussis, Hepatitis B, Poliomyelitis, Haemophilus influenzae b, and Meningococcal Serogroup C Combination Vaccine Administered to Infants at 2, 4 and 12 Months of Age
    Franck Thollot, David W. Scheifele, Heidemarie Pankow-Culot, Brigitte Cheuvart, Maarten Leyssen, Liliana Ulianov, Jacqueline M. Miller · 2014 · The Pediatric Infectious Disease Journal
36. Different Long-Term Duration of Seroprotection against Neisseria meningitidis in Adolescents and Middle-Aged Adults after a Single Meningococcal ACWY Conjugate Vaccination in The Netherlands
    Milou Ohm, Debbie M. van Rooijen, Axel A. Bonačić Marinović, Mariëtte B. van Ravenhorst, Marieke van der Heiden, Anne‐Marie Buisman, Elisabeth A. M. Sanders, Guy A. M. Berbers · 2020 · Vaccines
37. Exploring the population-level impact of MenB vaccination via modeling: Potential for serogroup replacement
    Cosmina S. Hogea, Thierry P Van Effelterre, Andrew Vyse · 2015 · Human Vaccines & Immunotherapeutics
38. Vacuna conjugada frente al meningococo C: impacto del programa de vacunación y efectividad a largo plazo en Navarra, 2000-2014
    Desirée Morales, Manuel Garcìa Cenoz, Laura Moreno‐Galarraga, Enrique Bernaola, Aurelio Barricarte, Jesús Castilla · 2016 · Enfermedades Infecciosas y Microbiología Clínica
39. Evolution of Vaccines Formulation to Tackle the Challenge of Anti-Microbial Resistant Pathogens
    Francesco Tognetti, Massimiliano Biagini, Maxime Denis, Francesco Berti, Domenico Maione, Daniela Stranges · 2023 · International Journal of Molecular Sciences
40. Protocol for a controlled human infection with genetically modifiedNeisseria lactamicaexpressing the meningococcal vaccine antigen NadA: a potent new technique for experimental medicine
    Diane F. Gbesemete, Jay R. Laver, Hans de Graaf, Muktar Ibrahim, Andrew Vaughan, Saul N. Faust, Andrew R. GORRINGE, Robert Charles Read · 2019 · BMJ Open
41. Advances in meningococcal vaccines
    Mariagrazia Pizza, Lisa M DeTora, James Wassil · 2012 · Clinical Practice
42. Hospitalization rates and outcome of invasive bacterial vaccine-preventable diseases in Tuscany: a historical cohort study of the 2000–2016 period
    Elena Chiappini, Federica Inturrisi, Elisa Orlandini, Maurizio de Martino, Chiara de Waure · 2018 · BMC Infectious Diseases
43. Preclinical evaluation of MenB vaccines: prerequisites for clinical development
    Holly Sanders, Patricia Kaaijk, Germie P. J. M. van den Dobbelsteen · 2012 · Expert Review of Vaccines
44. Use of Cost-Effectiveness Analyses for Decisions About Vaccination Programs for Meningococcal Disease in the United States, United Kingdom, The Netherlands, and Canada
    Liping Huang, Josephine Mauskopf, Ray Farkouh, Catherine Masaquel · 2021 · Expert Review of Vaccines
45. Protecting UK adolescents and adults against meningococcal serogroup B disease
    Andrew Vyse, Gillian Ellsbury, Harish Madhava · 2018 · Expert Review of Vaccines
46. The Impact of Nucleotide Sequence Analysis on Meningococcal Vaccine Development and Assessment
    Martin C. J. Maiden · 2019 · Frontiers in Immunology
47. cgMLST characterisation of invasive Neisseria meningitidis serogroup C and W strains associated with increasing disease incidence in the Republic of Ireland
    Robert Mulhall, Désirée E. Bennett, Holly B. Bratcher, Keith A. Jolley, James E. Bray, Piaras P. O’Lorcain, Suzanne M. Cotter, Martin C. J. Maiden, Robert Cunney · 2019 · PLoS ONE
48. Risk Analysis by Age on the Burden of Meningococcal Disease in Spain
    Irene Rivero Calle, Peter Francis Raguindin, Jacobo Pardo‐Seco, Federico Martinón‐Torres · 2022 · Vaccines
49. Carriage and transmission of Neisseria meningitidis
    Caroline L. Trotter, Martin C. J. Maiden · 2016 · Springer eBooks
50. The new first-line defense: the potential of nasopharyngeal colonization in vaccine strategies
    Win-Yan Chan, Jonathan Cohen, Jeremy Brown · 2016 · Vaccine Development and Therapy
51. Meningococcal meningitis in Spain in the Horizon 2030: A position paper
    F.A. Moraga Llop, Elena Andradas, Luis Carlos Blesa Baviera, Rafael Cantón, Juan María González del Castillo, Federico Martinón‐Torres, Elena Moya, Antoni Trilla, Julio A. Vázquez, Rodolfo Villena et al. · 2024 · Revista Española de Quimioterapia
52. Invasive Meningococcal Disease in Brazil: a literature review
    Marcelle Moura Silveira, Alan J. A. McBride, Caroline L. Trotter · 2020 · VITTALLE - Revista de Ciências da Saúde
53. Does post-implementation vaccine effectiveness data support pre-implementation predictions of 4CMenB utility?
    Jamie Findlow, Ray Borrow · 2017 · Pathogens and Disease
54. Genetic Diversity of Meningococcal Serogroup B Vaccine Antigens among Carriage Isolates Collected from Students at Three Universities in the United States, 2015–2016
    Henju Marjuki, How-Yi Chang, Nadav Topaz, Melissa J. Whaley, Jeni T. Vuong, Alexander Junxiang Chen, Laurel T. Jenkins, Fang Hu, Susanna E. Schmink, Adam C. Retchless et al. · 2021 · mBio
55. Meningococcal Carriage among Household Contacts of Patients with Invasive Meningococcal Disease in Kathmandu, Nepal: A Longitudinal Study
    Supriya Sharma, Jyoti Acharya, Dominique A. Caugant, Shreedhar Aryal, Megha Raj Banjara, Prakash Ghimire, Anjana Singh · 2021 · Pathogens
56. 24 year outcomes of hepatitis B vaccination in Hangzhou, China
    Jian Du, Yuyang Xu, Jun Wang, Shijun Liu, Yan Liu, Xiaoping Zhang, Xu ErPing · 2015 · Human Vaccines & Immunotherapeutics
57. Expected and Unexpected Effects of Vaccination
    Federico Martinón‐Torres · 2017 · Springer eBooks
58. Latin American Forum on Meningococcal Disease, Latin American Update: Its Prevention
    Pío López · 2022 · Archives of Pediatrics
59. NMR study of mutations of glycine-52 of the catalytic domain of diphtheria toxin
    Simon Sauvé, Geneviève Gingras, Yves Aubin · 2017 · Journal of Pharmaceutical and Biomedical Analysis
60. Calendario de vacunaciones de la Asociación Española de Pediatría: recomendaciones 2014
    David Moreno‐Pérez, Francisco José Álvarez García, J. Arístegui Fernández, María José Cilleruelo Ortega, J.M. Corretger Rauet, N. García Sánchez, Ángel Hernández Merino, T. Hernández-Sampelayo Matos, Manuel Merino Moína, Luis Ortigosa del Castillo et al. · 2014 · Vacunas
61. The difficult road to new vaccines for pertussis and serogroup B meningococcal disease
    Andrew R. GORRINGE · 2015 · Journal of Chemical Technology & Biotechnology
62. Seroprevalence of meningococcal serogroup C bactericidal antibodies in the Portuguese population, a decade after vaccine introduction in the National Immunisation Programme
    Paulo Gonçalves, Emma Sáez-López, Sofia Carneiro, Maria João Simões · 2021 · PLoS ONE
63. [From a pathogen's genome to an effective vaccine: the four-component meningococcal serogroup B vaccine].
    Raquel Abad, Federico Martinón‐Torres, Marı́a Elena Santolaya, Angelika Banzhoff, Carmen González-Inchausti, María Gabriela Graña, Julio A. Vázquez · 2019 · Europe PMC (PubMed Central)
64. Meningococcal Quadrivalent (Serogroups A, C, W135 and Y) Tetanus Toxoid Conjugate Vaccine (Nimenrix )
    Jamie Findlow, Paula Kriz, David Pace · 2012
65. Where next? The emergence of hypervirulent W meningococcus in the Netherlands
    Jonathan Broad, Matthew D. Snape · 2017 · The Lancet Public Health
66. Incidência da Doença Meningocócica no Rio Grande do Sul entre 2014 a 2018
    Adriana Heuert, Ana Lise Barbosa Soares, Marcelle Moura Silveira · 2020 · VITTALLE - Revista de Ciências da Saúde
67. Vaccine-preventable meningitis in French children with incorrect vaccination status from 2011 to 2013
    Jeanne Truong, Corinne Lévy, Sonia Prot‐Labarthe, HP Nguyen, E. Grimprel, Albert Faye, Robert Cohen, Mathie Lorrot · 2019 · Archives de Pédiatrie
68. One disease, two vaccines: challenges in prevention of meningococcal disease
    Cyra Patel, Clayton K Chiu, Frank Beard, Nigel W. Crawford, Kristine K. Macartney · 2020 · The Medical Journal of Australia
69. Análise e determinação de custos específicos e consequências econômico-sociais na incorporação da vacina contra meningite e doença meningocócica C conjugada na rotina do Programa Nacional de Imunização/PNI
    Alexander Itria · 2011
70. Protection against Neisseria meningitidis nasopharyngeal colonization relies on antibody opsonization and phagocytosis by neutrophils
    Elissa G. Currie, Olga L. Rojas, Isaac S. Lee, Khashayar Khaleghi, Alberto Martín, Jennifer L. Gommerman, Scott D. Gray‐Owen · 2024 · bioRxiv (Cold Spring Harbor Laboratory)
71. Consultation report - gonococcal immunoassays and standards for vaccine development
    Calman Alexander MacLennan, P. Davis, S.L. Gottlieb, Kate L. Seib, O.B. Harrison, J. A. Duncan, Andrew R. GORRINGE, Alison K. Criss, Ann E. Jerse, M.W. Russell et al. · 2026 · Vaccine
72. Vaccins anti-méningococciques: des politiques vaccinales et des recommandations hétérogènes
    D Gendrel · 2012 · Archives de Pédiatrie
73. Seroprevalence of antibodies against serogroup C meningococci in the region of Valencia, Spain: Impact of meningococcal C conjugate vaccination
    Lina Pérez–Breva, Raquel Abad, Miguel A. Martínez‐Beneito, Joan Puig‐Barberà, Sara Alemán-Sánchez, Nuria Morant Talamante, Macrina Sastre-Cantón, Julio A. Vázquez, Javier Díez‐Domingo · 2017 · Vaccine
74. Evidence for Rise in Meningococcal Serogroup C Bactericidal Antibody Titers in the Absence of Booster Vaccination in Previously Vaccinated Children
    Al-Mamoon M. Badahdah, Ameneh Khatami, Mohamed Tashani, Harunor Rashid, Robert Booy · 2017 · The Pediatric Infectious Disease Journal
75. Info-vaccins
    Robert Cohen, F. Vié le Sage, E. Grimprel · 2015 · Archives de Pédiatrie
76. Meningococcal Vaccines Directed at Capsular Group B
    David S. Stephens, Dan M. Granoff, Andrew John Pollard, Lee H. Harrison · 2023 · Elsevier eBooks
77. Surveillance of invasive meningococcal disease in the south of Brazil: considerations of immunization programme
    Marcelle Moura Silveira, Pedro Augusto Crespo, Neida Lucia Conrad, Thaís Larré Oliveira, Daiane Drawanz Hartwig, Caroline L. Trotter · 2021 · Journal of Medical Microbiology · Retracted
78. Historical review of vaccination against meningococcus in Spain (1996–2021). Learned lessons
    Angel Valls-Arévalo, Auxiliadora Fernández de Alba, David López-Martín, Walter Alfredo Goycochea-Valdivia, Irene Maté Cano, Marta García-Fernández de Villalta, Ignacio Salamanca de la Cueva, María Garcés‐Sánchez · 2023 · Vacunas (English Edition)
79. The experiences and perceptions of mothers utilizing child health services
    Linda Jonker · 2012 · SUNScholar (Stellenbosch University)
80. Calendario de vacunaciones de la Asociación Espa˜ de Pediatría: recomendaciones 2014
    David Moreno‐Pérez, Corretger Rauet, N. García Sánchez, Ángel Hernández Merino, Teresa Hernández‐Sampelayo, Manuel Merino Moína, Luis Ortigosa del Castillo, Jesús Ruíz-Contreras · 2016
81. Kinetics of Meningococcal Serogroup C-Specific Functional Antibody Levels Up to 15 Years after a Single Immunization with a Meningococcal Serogroup C Conjugate Vaccine during Adolescence
    Susanne P. Stoof, Mariëtte B. van Ravenhorst, Debbie M. van Rooijen, Richarda M. de Voer, Fiona R.M. van der Klis, Greet J. Boland, Elisabeth A. M. Sanders, Guy A. M. Berbers, Peter F. M. Teunis · 2016 · Clinical and Vaccine Immunology
82. Eine für Alle – Alle für Eine(n)?
    Steffen Rabe · 2018 · Allgemeine Homöopathische Zeitung
83. Prevalência e fatores associados ao estado de portador de Neisseria spp. em núcleos familiares: estudo de base populacional
    Jaqueline Costa Lima · 2019
84. Papel del estado de portador en el control de enfermedades infecciosas y su relación con la vacunación
    Juan Carlos Sanz, Belén Ramos Blázquez · 2019 · Revista Madrileña de Salud Pública
85. Ökonomie und Public Health
    Christian Jesberger, Stefan Greß · 2021 · Sozialwissenschaftliche Gesundheitsforschung
86. A review analyzing what is COVID-19, its causes, pathogenesis, pathophysiology, and treatment
    Mohamed Hoosen Suleman · 2021 · Zenodo (CERN European Organization for Nuclear Research)
87. Stratégie vaccinale contre la Covid-19 au long terme : contrôle ou élimination ?
    Judith E. Mueller · 2021 · Actualité et dossier en santé publique
88. Impfungen für das Immungedächtnis – immer wieder oder einmalig?
    Clara Lehmann · 2022 · Der Internist
89. Expected and Unexpected Effects of Vaccination
    Federico Martinón‐Torres · 2021 · Springer eBooks
90. Evaluation of Meningococcal Serogroup C Bactericidal Antibodies after Primary Vaccination: A Multicentre Study, Italy
    Arianna Neri, Massimo Fabiani, Anna Maria Barbui, Caterina Vocale, Alessandro Miglietta, Cecilia Fazio, Anna Carannante, Annapina Palmieri, Paola Vacca, Luigina Ambrosio et al. · 2022 · Vaccines
91. Revisión histórica de la vacunación frente a meningococo en España (1996-2021). Lecciones aprendidas
    Angel Valls-Arévalo, Auxiliadora Fernández de Alba, David López-Martín, Walter Alfredo Goycochea-Valdivia, Irene Maté Cano, Marta García-Fernández de Villalta, Ignacio Salamanca de la Cueva, María Garcés‐Sánchez · 2022 · Vacunas
92. Surveillance of invasive meningococcal disease in southern Brazil: considerations of an immunization programme
    Marcelle Moura Silveira, Pedro Augusto Crespo, Neida Lucia Conrad, Thaís Larré Oliveira, Daiane Drawanz Hartwig, Caroline L. Trotter · 2023 · Journal of Medical Microbiology
93. Mitigating the risk of invasive meningococcal disease in the umrah setting: Epidemiology, surveillance, and vaccination strategies
    Abrar Alasmari, Najim Zafer Alshahrani, Yasser Bakhsh, Ahmad Alkhorisi, Ahmed A. Albarraq, Emad Almohammadi, Abdullah M. Alarifi, Haleema Alserehi, Abdullah Mufareh Assiri · 2026 · Journal of Infection and Public Health
94. Additional file 2 of Systematic literature review of the impact and effectiveness of monovalent meningococcal C conjugated vaccines when used in routine immunization programs
    Tin Tin Htar, Myint, Sally Jackson, Paul Balmer, Lidia Serra, Andrew Vyse, Slack, Mary, Margarita Riera-Montes, David L. Swerdlow, Jamie Findlow · 2020 · Figshare
95. Additional file 1 of Systematic literature review of the impact and effectiveness of monovalent meningococcal C conjugated vaccines when used in routine immunization programs
    Tin Tin Htar, Myint, Jackson, Sally, Paul Balmer, Lidia Serra, Andrew Vyse, Slack, Mary, Margarita Riera-Montes, David L. Swerdlow, Jamie Findlow · 2020 · Figshare
96. Additional file 1 of Carriage prevalence of Neisseria meningitidis in China, 2005–2022: a systematic review and meta-analysis
    Mengmeng Yue, Juan Xu, Yu, Jianxing, Shao, Zhujun · 2022 · Figshare
97. First Field Use of the Pentavalent Meningococcal Conjugate Vaccine (Men5CV) in Response to a Serogroup C Meningitis Outbreak: Evidence from Yobe State, Northeastern Nigeria
    Baba Waru Goni, Hamidu Suleiman Kwairanga, Olugbenga Oguntunde, Mohammed Isiaka, Ahmed Ibrahim Ba’aba, Musa Mohammed Baba, Habu Abdul, Muhammad Lawan Gana, Ibrahim Musa Kida, Bukar Bakki et al. · 2026 · Research Square
98. Designing Optimal Intervention Policies for Bacterial CNS Infection Dynamics With Encephalitic Progression: A Multicontrol Compartmental Model
    M. S. Rahman, Rehena Nasrin, Md. Haider Ali Biswas · 2026 · Complexity
99. Dynamic characteristics of Neisseria meningitidis carriage among new students in boarding martial arts schools: a longitudinal follow-up study
    Jun Li, Yingying Liu, Jiangnan Kong, Wang Xiaoli, Tian Tian, Xiangyang Zhang, Zhang Xiaoxiao, Yanfang Ji, Guo Yonghao, Qian Liu et al. · 2026 · Frontiers in Public Health